SwanBio Therapeutics, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2017-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.swanbiotx.com
A Study to Evaluate Administration of SBT101 Gene Therapy in Adult Patients With Adrenomyeloneuropathy (AMN)
Phase 1
Recruiting
- Conditions
- X-ALDAMN Gene MutationAMN
- Interventions
- Genetic: SBT101Procedure: Imitation Procedure
- First Posted Date
- 2022-05-27
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- SwanBio Therapeutics, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT05394064
- Locations
- 🇳🇱
Amsterdam UMC, Amsterdam, Netherlands
🇺🇸University of Massachusetts Chan Medical School, Worcester, Massachusetts, United States
Study of Disease Progression in Adults With Inherited Forms of Spastic Paraplegia
Active, not recruiting
- Conditions
- AMN Gene MutationAMNX-ALD
- Interventions
- Other: Natural History Observation
- First Posted Date
- 2021-08-17
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- SwanBio Therapeutics, Inc.
- Target Recruit Count
- 65
- Registration Number
- NCT05008874
- Locations
- 🇳🇱
Amsterdam UMC, Amsterdam, Netherlands
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸University of Utah, Salt Lake City, Utah, United States
© Copyright 2025. All Rights Reserved by MedPath